Sanofi Consumer Healthcare India
- Market cap
- ₹ 7,413 Cr.
- P/E
- 28.8x
- P/B
- 19.57x
- 52-week range
- 3,168.2 – 5,255
- ROE
- 72%
- ROCE
- 90%
- Dividend yield
- 2.3%
- Debt / equity
- 0.06
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Sanofi Consumer Healthcare India Limited is an India-based company. It is engaged in the business of manufacturing, producing, processing, marketing, formulating, buying, trading, storing, packing, selling, distributing, importing, exporting, providing consultancy and otherwise dealing in all kinds of varieties of pharmaceuticals, especially consumer healthcare products, including: basic drugs; drug intermediates; chemical, medical, biological and electrolytic drugs, ingredients, Medicare, preparations and compositions; medicines, preparations and formulations in all or any forms, including formulations in which various drugs are processed; patents, medicines, drugs enzymes, fermentations and generic products, vitamin and vitamins products tonic, food products, nutritional products, products in therapies such as pain care, allergy, digestive health, cough & cold, sleep, general wellness and hormones and hormone products, and ingredients of every kind and other articles, and compounds.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Sanofi Consumer Healthcare India against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)28.8 against a typical 34.3: cheaper than most peers (1st = cheapest).99th of 220
- Sales growth+6.8% against a typical +15.6% from a year earlier.126th of 197
- Profit growth+13.1% against a typical +18.9% from a year earlier.95th of 160
- Share price, 3 months−24.9% against a typical 0%.192nd of 200
- Size₹ 7,413.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).47th of 199
Latest announcements
Exchange filings and their impact on the company.
- Strong Q3 with 12% revenue and 22% profit growth signals sustained double-digit growth ahead.
Sanofi Consumer Healthcare India reported Q3 2026 revenue of Rs 263.1 crore, up 12% year-on-year, with domestic sales up 19%. Profit before tax rose 22% to Rs 102.7 crore and net profit rose to Rs 76.6 crore with EPS of Rs 33.26. For the nine months, revenue was Rs 728 crore up 16% and profit before tax was up 24%, showing profitable growth driven by volumes and relaunched brands.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 28 Oct 2026 | Financial Results | To consider and approve the Unaudited Financial Results for the quarter and nine months ended September 30, 2026 |
| 28 Jul 2026 | Financial Results | To consider and approve the Unaudited Financial Results for the quarter and half year ended Jun 30, 2026 |
| 28 Apr 2026 | Financial Results | To consider and approve the Unaudited Financial Results of the Company for the quarter ended March 31, 2026 |
| 25 Feb 2026 | Financial Results | To consider and approve the Audited Financial Statements for the Quarter and Financial Year ended December 31, 2025 |
| 12 Nov 2025 | Financial Results | To consider and approve the Unaudited Financial Results for the quarter and nine months ended 30th September 2025 |
| 4 Aug 2025 | Financial Results | To consider and approve the Unaudited Financial Results for the quarter and half-year ended 30th June 2025 |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 210 | 225 | 222 | 172 | 160 | 171 | 173 | 221 | 234 | 251 | 229 | 236 |
| Expenses | 116 | 135 | 140 | 109 | 97 | 109 | 109 | 151 | 149 | 161 | 140 | 146 |
| Operating Profit | 95 | 90 | 82 | 64 | 63 | 62 | 64 | 70 | 85 | 90 | 89 | 89 |
| OPM % | 45% | 40% | 37% | 37% | 39% | 36% | 37% | 32% | 36% | 36% | 39% | 38% |
| Other Income | 1 | 1 | 3 | −24 | 3 | 2 | 5 | 12 | 3 | 5 | 6 | 6 |
| Interest | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 95 | 90 | 84 | 39 | 61 | 63 | 67 | 79 | 84 | 90 | 91 | 92 |
| Tax % | 25% | 24% | 25% | 25% | 26% | 29% | 25% | 23% | 25% | 27% | 25% | 25% |
| Net Profit | 71 | 68 | 63 | 29 | 45 | 44 | 50 | 61 | 63 | 66 | 68 | 69 |
| EPS in Rs | — | — | — | 12.59 | 19.54 | 19.24 | 21.71 | 26.36 | 27.31 | 28.87 | 29.44 | 29.87 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 31%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 34%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 78%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sanofi Consumer Healthcare India | ₹ 3,471.50 | ₹ 7,413 Cr. | 28.8x | 19.6x | 72% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Amit Jain
- Independent Chairman of the Board
- Maithilee Kaizad Mistry
- Chief Financial Officer, Whole-Time Director
- Nikunjkumar Jaysukhlal Savaliya
- Compliance Officer, Company Secretary
- Himanshu Bakshi
- Managing Director, Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.